• Luis Peñarrubia, Maria Ruiz, Roberto Porco, Sonia N Rao, Martí Juanola-Falgarona, Davide Manissero, Marta López-Fontanals, and Josep Pareja.
• STAT-Dx Life, S.L. (a QIAGEN Company), Baldiri Reixac, 4-8, 08028 Barcelona, Spain.
• Int. J. Infect. Dis. 2020 Aug 1; 97: 225-229.

ObjectivesIn this study, five SARS-CoV-2 PCR assay panels were evaluated against the accumulated genetic variability of the virus to assess the effect on sensitivity of the individual assays.Design Or MethodsAs of week 21, 2020, the complete set of available SARS-CoV-2 genomes from GISAID and GenBank databases were used in this study. SARS-CoV-2 primer sequences from publicly available panels (WHO, CDC, NMDC, and HKU) and QIAstat-Dx were included in the alignment, and accumulated genetic variability affecting any oligonucleotide annealing was annotated.ResultsA total of 11,627 (34.38%) genomes included single mutations affecting annealing of any PCR assay. Variations in 8,773 (25.94%) genomes were considered as high risk, whereas additional 2,854 (8.43%) genomes presented low frequent single mutations and were predicted to yield no impact on sensitivity. In case of the QIAstat-Dx SARS-CoV-2 Panel, 99.11% of the genomes matched with a 100% coverage all oligonucleotides, and critical variations were tested in vitro corroborating no loss of sensitivity.ConclusionsThis analysis stresses the importance of targeting more than one region in the viral genome for SARS-CoV-2 detection to mitigate the risk of loss of sensitivity due to the unknown mutation rate during this SARS-CoV-2 outbreak.Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

24 keywords...

hide…